Bristol-Myers, Celgene Get FTC Request For More Info
March 26 2019 - 7:57AM
Dow Jones News
By Colin Kellaher
Bristol-Myers Squibb Co. (BMY) on Tuesday said the U.S. Federal
Trade Commission has requested more information as part of its
antitrust review of the company's planned $74 billion acquisition
of Celgene Corp. (CELG).
The New York biopharmaceutical company said the so-called
"second request" from the FTC involves a review of marketed and
pipeline products for the treatment of psoriasis.
Bristol-Myers said the companies plan to work with the FTC to
show that the deal won't harm competition.
Bristol-Myers said the FTC's request extends the antitrust
waiting period for the deal, but said it still expects to complete
the Celgene acquisition in the third quarter.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 26, 2019 07:42 ET (11:42 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jul 2024 to Jul 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jul 2023 to Jul 2024